- Home
- FEMY vs ALGS Comparison
FEMY vs ALGS Comparison
Compare FEMY & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FEMY | ALGS |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.2M | 40.6M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FEMY | ALGS |
|---|---|---|
| Price | $0.42 | $7.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $5.50 | ★ $39.33 |
| AVG Volume (30 Days) | ★ 584.4K | 36.9K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 44.71 | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,293,313.00 | $2,186,000.00 |
| Revenue This Year | $59.47 | $4.99 |
| Revenue Next Year | $150.54 | $8.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 40.77 | N/A |
| 52 Week Low | $0.31 | $3.76 |
| 52 Week High | $1.29 | $13.69 |
Technical Indicators
Market Signals| Indicator | FEMY | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 38.98 | 60.05 |
| Support Level | $0.33 | $7.61 |
| Resistance Level | $0.58 | $8.30 |
| Average True Range (ATR) | 0.05 | 0.55 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 36.31 | 91.76 |
Price Performance
Historical ComparisonAbout FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.